Skip to content

Frontlight ResearchEarly access

Trial site

Chase Medical Research, LLC

Waterbury, Connecticut 06708, United StatesNot linked to an institution yet

26running trials
20closed trials

The trials here

What the 46 trials at this site are about, from their registry records.

Conditions: Obesity27 trials
Type 2 diabetes18 trials
Coronary artery disease5 trials
Osteoarthritis5 trials
High blood pressure4 trials
Migraine4 trials
Stroke4 trials
Chronic kidney disease3 trials
Familial hypercholesterolaemia2 trials
Lyme disease2 trials
Obstructive sleep apnoea2 trials
Diabetic eye disease1 trial
and 3 more
Phase: Phase 337 trials
Phase 26 trials
Phase 1/21 trial
Phase 2/31 trial
Phase 41 trial
Status: Completed18 trials
Active, not recruiting13 trials
Recruiting10 trials
Not yet recruiting3 trials
Terminated1 trial
Withdrawn1 trial
Lead sponsor: Eli Lilly and Company19 trials
Novo Nordisk A/S9 trials
Novartis Pharmaceuticals4 trials
Amgen3 trials
Pfizer3 trials
and 7 more

Running trials

Not yet recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633· Phase 3· Eli Lilly and Company· Source
Contact: Joseph Soufer (principal investigator)
Not yet recruiting
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
NCT07919405· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
NCT07817251· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579· Phase 3· Eli Lilly and Company· Source
Contact: Joseph Soufer (principal investigator)
Recruiting
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07674654· Phase 3· TriGemX Bio, Inc.· Source
Contact: Annemarie Vance
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
NCT07684235· Phase 3· Amgen· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07645924· Phase 3· TriGemX Bio, Inc.· Source
Contact: Annemarie Vance
Active, not recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07509307· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07481630· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190· Phase 3· Eli Lilly and Company· Source
Contact: Joseph Soufer (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· Phase 3· Eli Lilly and Company· Source
Contact: Jenna Langello (principal investigator)
Active, not recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471· Phase 3· Eli Lilly and Company· Source
Recruiting
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
NCT07136012· Phase 3· Amgen· Source
Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839· Phase 3· Amgen· Source
Active, not recruiting
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
NCT06577090· Phase 2· Skye Bioscience, Inc.· Source
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252· Phase 2· Eli Lilly and Company· Source
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
NCT03811561· Phase 3· Novo Nordisk A/S· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Obesity8 recruiting
Type 2 diabetes5 recruiting
Migraine2 recruiting
Osteoarthritis2 recruiting
Coronary artery disease1 recruiting
High blood pressure1 recruiting

Closed trials

Withdrawn
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
NCT07357766· Phase 3· Novo Nordisk A/S· Source
Completed
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
NCT06926842· Phase 2· Zealand Pharma· Source
Completed
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
NCT06542874· Phase 2· Novo Nordisk A/S· Source
Completed
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· Phase 3· Boehringer Ingelheim· Source
Completed
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367· Phase 3· Eli Lilly and Company· Source
Completed
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
NCT05975099· Phase 1/2· ModernaTX, Inc.· Source
Completed
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066· Phase 3· Eli Lilly and Company· Source
Completed
Safety and Efficacy Study of S-309309 in Obese Adults
NCT05925114· Phase 2· Shionogi· Source
Completed
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
NCT05882045· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
NCT05662332· Phase 3· Eli Lilly and Company· Source
Completed
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
NCT05514535· Phase 3· Novo Nordisk A/S· Source
Completed
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
NCT05207865· Phase 4· Pfizer· Source
Completed
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
NCT05275400· Phase 3· Eli Lilly and Company· Source
Completed
A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
NCT05047263· Phase 3· Bayer· Source
Terminated
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
NCT04804033· Phase 2/3· Pfizer· Source
Completed
Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
NCT04801420· Phase 2· Pfizer· Source
Completed
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT04255433· Phase 3· Eli Lilly and Company· Source
Completed
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
NCT04023552· Phase 3· Novartis Pharmaceuticals· Source
Completed
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
NCT04184622· Phase 3· Eli Lilly and Company· Source

Site data: ClinicalTrials.govUpdated 14 Nov 2026

Report an error